Q-omics provides the consensus-scored FAM25C profile across patient tissues and cancer cell-line models. FAM25C expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM25C is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, FAM25C RNA expression shows 7,013 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCEC, LUSC, and ESCA as cancer lineages where FAM25C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM25C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM25C survival associations across molecular data types. FAM25C RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM25C RNA expression–survival associations across cancer types. High FAM25C expression shows unfavorable associations in UCEC, OV, PAAD, SKCM, STAD and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM25C RNA expression.
This table summarizes FAM25C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM25C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM25C shows lower tumor expression in READ and higher tumor expression in LUSC. The LUSC box plot shows higher FAM25C RNA expression in tumor versus normal tissue (log2 FC = +0.224, t-test p < 0.001).
This table shows molecular features associated with FAM25C in patient tissues and cancer cell lines. In patient samples, FAM25C shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM25C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
